Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PHV02 Nipah Vaccine in Healthy Adults
NCT06221813Phase 1Completed
- Sponsor
- Public Health Vaccines LLC
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PHV02 in Nipah virus infection (NiV) (8 cohorts), sponsored by Public Health Vaccines LLC. Primary endpoints: Percentage of participants with local injection site and systemic adverse events, Percentage of participants with joint related symptoms, rash and unsolicited AEs and 5 more. Started Jan 2024; status: completed.
02
Drugs
PHV02
03
Conditions
Nipah virus infection (NiV)
Beyond the preview
Go deeper on NCT06221813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221813.